Detail

Study ID: ECOG-ACRIN EA5163

Title:

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region, Thief River Falls, Worthington
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Non-Small Cell Lung Cancer
Stage:
Phase III
Status:
Active - Open to Accrual